OBD strengths commercial leadership

Oxford BioDynamics PLC

08 November 2023

 

Oxford BioDynamics Plc

Oxford BioDynamics strengthens commercial leadership with new SVP of Business and Corporate Development

·   Appointment of industry veteran Dr Steven Arrivo as SVP business and corporate development.

·   Dr Arrivo to focus on marketing, partnering and sales of the recently launched EpiSwitch Prostate Screening (PSE) test.

Oxford, UK - 8 November, 2023 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform has appointed Dr Steven Arrivo as Senior Vice President of Business and Corporate Development. Dr Arrivo brings over 20 years of science and industry experience along with an established track record in business and corporate development within personalized medicine across big pharma, biotech and molecular diagnostics companies.

Dr Arrivo joins Oxford BioDynamics from CellCarta Biosciences (formerly Caprion) where he spent five years in Business Development, as Senior Director and Vice President. Prior to that he was at Biodesix and Ventana Medical Systems. Before then, he spent four years at Pfizer in various R&D roles and he began his career at Merck & Co., Inc. as a Senior Project Scientist following several academic research positions. Dr Arrivo holds a Bachelor's degree in Chemistry from the University of Eastern Illinois, and a Master's degree in Synthetic Organic and Inorganic Chemistry and Ph.D. in Physical Chemistry from Northwestern University. He completed Postdoctoral studies in Physical Chemistry at Columbia University.

At OBD, Dr Arrivo's role will be to implement effective marketing and sales strategies for the newly launched EpiSwitch® PSE prostate cancer detection test. His specific focus will be to grow sales in the US market, where he has considerable experience of launching products.

Dr Jon Burrows, CEO of Oxford BioDynamics, commented:

"Having someone of Steve's calibre in the OBD commercial team is a real endorsement of our technology and its potential. He has a wealth of experience in this industry and the ideal skill set to drive our commercial efforts with PSE. His leadership and knowledge will be invaluable across all areas of our growing product portfolio."

"While it is currently early days for the PSE test in the market, the signs are promising. We have work to do so establish ourselves fully in the testing market, but appointments of this quality are crucial in strengthening and furthering our progress towards that goal."

-Ends-

For further details please contact:

Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO	[phone]
Shore Capital Nominated Adviser and Broker Stephane Auton Iain Sexton	[phone]
Instinctif Partners Melanie Toyne-Sewell Rozi Morris Jack Kincade	[phone] [e-mail]

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer, which has been launched in the US and UK in September 2023.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit, which is available for purchase by the life science research community.

The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow OBD on Twitter (@OxBioDynamics) and LinkedIn.

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 15,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

 

END